Singapore markets closed

JNJ Aug 2024 135.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.8300-0.0200 (-2.35%)
At close: 11:58AM EDT
Full screen
Previous close0.8500
Open0.8500
Bid0.7300
Ask0.8000
Strike135.00
Expiry date2024-08-16
Day's range0.8300 - 0.8600
Contract rangeN/A
Volume18
Open interest3.66k
  • PR Newswire

    Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study

    Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the Phase 2 DAHLIAS dose-ranging study of nipocalimab in adult patients living with Sjögren's disease (SjD). Response was demonstrated as early as Week 4 and continued to increase throughout the 24-week treatment period compared with patients recei

  • Zacks

    Johnson & Johnson (JNJ) Could Be a Great Choice

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • PR Newswire

    TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

    Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy.1 These data, featured in a poster presentation at the 2024 European